161 related articles for article (PubMed ID: 22690082)
61. TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer.
Spindler KL; Christensen IJ; Nielsen HJ; Jakobsen A; Brünner N
Tumour Biol; 2015 Jun; 36(6):4301-8. PubMed ID: 25608838
[TBL] [Abstract][Full Text] [Related]
62. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.
Lee KW; Lee SS; Kim SB; Sohn BH; Lee HS; Jang HJ; Park YY; Kopetz S; Kim SS; Oh SC; Lee JS
Clin Cancer Res; 2015 Jan; 21(2):357-64. PubMed ID: 25388162
[TBL] [Abstract][Full Text] [Related]
63. The efficacy and safety of panitumumab in the treatment of patients with metastatic colorectal cancer: a meta-analysis from five randomized controlled trials.
Liang RF; Zheng LL
Drug Des Devel Ther; 2015; 9():4471-8. PubMed ID: 26300630
[TBL] [Abstract][Full Text] [Related]
64. Overall survival of patients with KRAS wild-type tumor treated with FOLFOX/FORFIRI±cetuximab as the first-line treatment for metastatic colorectal cancer: A meta-analysis.
Yang YF; Wang GY; He JL; Wu FP; Zhang YN
Medicine (Baltimore); 2017 Mar; 96(12):e6335. PubMed ID: 28328812
[TBL] [Abstract][Full Text] [Related]
65. Cetuximab-based therapy vs noncetuximab therapy in advanced or metastatic colorectal cancer: a meta-analysis of seven randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Mo Z; Gao F
Colorectal Dis; 2010 May; 12(5):399-406. PubMed ID: 19508512
[TBL] [Abstract][Full Text] [Related]
66. Role of first-line anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy in advanced colorectal cancer: a meta-analysis of randomized clinical trials.
Khattak MA; Martin H; Davidson A; Phillips M
Clin Colorectal Cancer; 2015 Jun; 14(2):81-90. PubMed ID: 25666296
[TBL] [Abstract][Full Text] [Related]
67. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.
Huang F; Xu LA; Khambata-Ford S
Clin Cancer Res; 2012 Feb; 18(4):1156-66. PubMed ID: 22294722
[TBL] [Abstract][Full Text] [Related]
68. Standard chemotherapy with cetuximab for treatment of colorectal cancer.
Li XX; Liang L; Huang LY; Cai SJ
World J Gastroenterol; 2015 Jun; 21(22):7022-35. PubMed ID: 26078581
[TBL] [Abstract][Full Text] [Related]
69. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
[TBL] [Abstract][Full Text] [Related]
70. Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
Mekenkamp LJ; Tol J; Dijkstra JR; de Krijger I; Vink-Börger ME; van Vliet S; Teerenstra S; Kamping E; Verwiel E; Koopman M; Meijer GA; van Krieken JH; Kuiper R; Punt CJ; Nagtegaal ID
BMC Cancer; 2012 Jul; 12():292. PubMed ID: 22804917
[TBL] [Abstract][Full Text] [Related]
71. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
De Roock W; Claes B; Bernasconi D; De Schutter J; Biesmans B; Fountzilas G; Kalogeras KT; Kotoula V; Papamichael D; Laurent-Puig P; Penault-Llorca F; Rougier P; Vincenzi B; Santini D; Tonini G; Cappuzzo F; Frattini M; Molinari F; Saletti P; De Dosso S; Martini M; Bardelli A; Siena S; Sartore-Bianchi A; Tabernero J; Macarulla T; Di Fiore F; Gangloff AO; Ciardiello F; Pfeiffer P; Qvortrup C; Hansen TP; Van Cutsem E; Piessevaux H; Lambrechts D; Delorenzi M; Tejpar S
Lancet Oncol; 2010 Aug; 11(8):753-62. PubMed ID: 20619739
[TBL] [Abstract][Full Text] [Related]
72. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
De Roock W; Piessevaux H; De Schutter J; Janssens M; De Hertogh G; Personeni N; Biesmans B; Van Laethem JL; Peeters M; Humblet Y; Van Cutsem E; Tejpar S
Ann Oncol; 2008 Mar; 19(3):508-15. PubMed ID: 17998284
[TBL] [Abstract][Full Text] [Related]
73. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer.
Price T; Kim TW; Li J; Cascinu S; Ruff P; Suresh AS; Thomas A; Tjulandin S; Guan X; Peeters M
Eur J Cancer; 2016 Nov; 68():51-59. PubMed ID: 27716478
[TBL] [Abstract][Full Text] [Related]
74. Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials.
Liu L; Cao Y; Tan A; Liao C; Gao F
Cancer Chemother Pharmacol; 2010 Apr; 65(5):849-61. PubMed ID: 19680654
[TBL] [Abstract][Full Text] [Related]
75. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.
Pentheroudakis G; Kotoula V; De Roock W; Kouvatseas G; Papakostas P; Makatsoris T; Papamichael D; Xanthakis I; Sgouros J; Televantou D; Kafiri G; Tsamandas AC; Razis E; Galani E; Bafaloukos D; Efstratiou I; Bompolaki I; Pectasides D; Pavlidis N; Tejpar S; Fountzilas G
BMC Cancer; 2013 Feb; 13():49. PubMed ID: 23374602
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta-analysis.
Lin LI; Chen LL; Wang Y; Meng XY; Liang C; Zhou FX
Mol Clin Oncol; 2016 Jun; 4(6):1017-1024. PubMed ID: 27284437
[TBL] [Abstract][Full Text] [Related]
77. Correlation of cetuximab-induced skin rash and outcomes of solid tumor patients treated with cetuximab: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 Feb; 93(2):127-35. PubMed ID: 25139841
[TBL] [Abstract][Full Text] [Related]
78. [Efficacy of cetuximab in therapy of metastatic colorectal cancer: a system evaluation].
Hou SH; Liang XB; Bai WQ; Yang J; Yan D; Zhang X; Wang LC
Zhonghua Yi Xue Za Zhi; 2009 May; 89(20):1387-90. PubMed ID: 19671328
[TBL] [Abstract][Full Text] [Related]
79. Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer.
Sartore-Bianchi A; Di Nicolantonio F; Nichelatti M; Molinari F; De Dosso S; Saletti P; Martini M; Cipani T; Marrapese G; Mazzucchelli L; Lamba S; Veronese S; Frattini M; Bardelli A; Siena S
PLoS One; 2009 Oct; 4(10):e7287. PubMed ID: 19806185
[TBL] [Abstract][Full Text] [Related]
80. Prognostic value of PTEN in
Zhang JY; Kong YY; Wang QF; Yang YJ; Liu Z; Lin N; Ye DW; Dai B
Asian J Androl; 2022; 24(1):50-55. PubMed ID: 34100390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
